भारत सरकार | GOVERNMENT OF INDIA
inner page banner

FAQ's

21. Whether approval of the NBA is required for accessing commercially available varieties/hybrid seeds from the market solely for the purpose of investigating potential infringement of my proprietary line/variety/hybrid?

No, when biological resources are used solely for testing of infringement of commercially available biological resources (hybrid/variety), it will not attract the provisions of the BD Act.

22. Do the non-Indian scientists/researchers/students visiting herbaria/ museum/universities for comparing the species with the holotype/ herbaria/other samples available with these institutions; including BSI/ZSI/universities, require prior approval of the N

No. Scientists, researchers, and students are not required to obtain prior approval from the NBA for comparing holotype or herbarium samples within institutions such as herbaria, museums, universities, BSI, or ZSI. However, prior approval from the NBA is mandatory for taking such materials outside India.

23. Whether permission of the NBA is required for IPR if a biological resource is procured from the market or a trader?

Yes, permission from the NBA is required even if a biological resource is procured/ accessed from the market or a trader.

24. Who has the authority to classify a material as a biological resource, derivative, or value-added product under the BD Act?

The responsibility for determining whether a material qualifies as a value-added product, biological resource, or derivative lies with the NBA. The NBA reviews each application on a “case-by-case basis”, considering the nature of the resource, how it aligns with the definitions provided under the Act and Rules.

25. Is a transferee free to use the obtained results of research from the transferor?

  • No. If the transferee {Section 3(2) entity} wants to utilise the obtained results of research for further research, they need to register with the NBA in Form-4.
  • Similarly, for further commercial utilisation of the results of the research, prior approval of the NBA has to be obtained in Form-5. For obtaining any IPR within or outside India, prior approval from the NBA is required in Form-6 as per Rule 15 of the BD Rules,2024.
  • In the case of accessing biological resources along with the obtained results of research for further research, prior approval from the NBA is required in the application in Form -1.

26. What are the activities regulated under the BD Act after coming into force of the BD (Amendment) Act, 2023?

S.noActivitySection 7 personSection 3(2) person
1ResearchNo approval is requiredPrior approval from the NBA is mandatory
2Bio-survey and Bio-utilizationNo approval is requiredPrior approval from the NBA is mandatory
3Commercial utilizationPrior intimation (Approval) from the SBB/UTBC is required. [State/UT from whose jurisdiction the bioresources are to be accessed]Prior approval from the NBA is mandatory
4For obtaining any IPRPrior registration with NBA is mandatoryPrior approval from the NBA is mandatory
5Commercialization of any IPRPrior approval from the NBA is mandatoryPrior approval from the NBA is mandatory
6Sharing or transferring the results of research to Section 3(2) person for monetary consideration or otherwisePrior approval from the NBA is mandatoryPrior approval from the NBA is mandatory
7Using the results of research obtained through transfer for further research by the transferee {Section 3(2) entity}Not applicablePrior registration with NBA is mandatory
8Using the results of research obtained through transfer for commercial utilization by the transferee {Section 3(2) entity}Not applicablePrior approval from the NBA is mandatory
9Using the results of research for obtaining IPR by the transferee {Section 3(2) entity}Not applicablePrior approval from the NBA is mandatory
10Conducting non-commercial research or research for emergency purposes outside India by Indian researcher or institutionPrior approval from the NBA is mandatoryNot applicable
11Utilization of biological resource or TK associated thereto obtained from any foreign country for research or for commercial purpose or for obtaining IPR in IndiaDeclaration to NBA is mandatoryDeclaration to NBA is mandatory
12Deposition of micro-organisms by Indian researchers/scientist in the repositories of other country for claim of discovery of novel species for publication in journalsPrior intimation to NBA is mandatoryNA
The relevant application forms and fees are provided in the BD Rules, 2024

27. What is the benefit-sharing obligation for undertaking research by Section 3(2) applicants?

If a Section 3(2) applicant accesses certain biological resources, including digital sequence information or knowledge associated thereto, for research, the applicant has to pay the upfront payment as determined by the NBA. However, this upfront payment is not applicable in cases where the research is undertaken for academic purposes.

28. Are the biological resources notified under Section 40 of the BD Act exempt from the various provisions of the BD Act, particularly in relation to IPR?

The biological resources notified under Section 40 of the BD Act are exempted when normally traded as commodities. However, obtaining IPR for the inventions based on the use of such notified biological resources is not exempt from the provisions of the Act.

29. Do the provisions of the BD Act contradict those of the Forest Rights Act, 2006 with respect to access and management of forest resources by the local communities?

There is no contradiction between the provisions of the two Acts regarding access/management of forest resources by the local communities as Section 7 of the BD Act clearly states that the local people and communities of the area, including growers and cultivators of biodiversity, are exempted from the provisions of the BD Act, 2002.

Further, Section 59 of the BD Act states that the provisions of this Act shall be in addition to and not in derogation of the provisions of any other law, for the time being in force, relating to forests or wildlife. This ensures legal harmony between the BD Act and other environmental / forest related legislations including the Forest Rights Act, 2006.

30. I am based in Germany and plan to access the DNA sequence of a microorganism from a German microbial repository. The DNA sequence of microorganism was deposited by an Indian scientist in the past. What are my obligations under the BD Act?

Prior approval of the NBA is required before accessing the DNA sequence from a foreign microbial repository for undertaking research. You must apply in Form-1, as accessing the biological resources occurring in or obtained from India or digital sequence information on biological resources which are accessed from India, including those deposited in repositories outside India, is regulated under the provisions of the BD Act.

31. Is there any prescribed application form for seeking approval of the NBA to access biological resources or associated knowledge or both by a non-Indian natural or legal person for undertaking research or for bio-survey and bio-utilization?

Yes. Both foreign individuals and entities fall under Section 3(2) of the Act. Hence, such persons have to obtain prior approval of the NBA by applying in Form-1 for access to biological resources or knowledge associated thereto for research or bio-survey and bio-utilisation as per Rule 13 of the BD Rules, 2024.

32. If a person acquires biological resources or associated TK from outside India which is of foreign origin for research, commercial utilization, or for obtaining IPR in India, does the applicant need approval from the NBA?

If an applicant acquires biological resources or associated TK from outside India for purposes such as research, commercial utilization, or seeking lPR in India, they are required to submit a declaration under Form-10 to the NBA. This declaration ensures that the NBA is notified of any access to biological resources or TK of foreign origin.

33. Who is considered as Section 3(2) person under the amended Act?

  1. a person who is not a citizen of India;
  2. a citizen of India, who is a non-resident as defined in clause (30) of Section 2 of the Income-tax Act, 1961;
  3. a body corporate, association or organization;
    1. Not incorporated or registered in India; or
    2. Incorporated or registered in India under any law for the time being in force, which is controlled by a foreigner within the meaning of clause (27) of Section 2 of the Companies Act, 2013.

34. Who determines the fair and equitable benefit-sharing component?

According to Section 2(g) of the Act, “fair and equitable benefit sharing” means sharing of benefits as determined by the NBA under Section 21.

Section 21 states that the NBA will determine the benefit sharing. The Authority in consultation with the local bodies impose terms and conditions while granting approvals, for securing equitable sharing of benefits.

35. Whether approval is necessary for publication of results of research on any biological resources occurring in India, in a research paper or for dissemination in any workshop or seminar?

No. Section 4 exempts publication of research papers on any biological resources occurring in or obtained or accessed from India or dissemination of knowledge in any seminar or workshop involving financial benefit, provided such publication or dissemination is in conformity with the guidelines issued by the Central Government.

36. Does the BD Act provide for any exemptions?

The Act provides for the following exemptions:

  1. Access by Section 7 entities for research / bio-survey / bio-utilization: Access to biological resources or knowledge associated thereto by a Section 7 entity for undertaking research or bio-survey and bio-utilisation in India is exempted from seeking approval of SBB/NBA under the Act.
  2. Value-added products: Access to value-added products, which may contain portions or extracts of plants and animals in unrecognisable and physically inseparable form {Sec. 2(p)}.
  3. Codified traditional knowledge and cultivated medicinal plants: Codified traditional knowledge, cultivated medicinal plants and their products, local people and communities of the area, including growers and cultivators of biodiversity and vaids, hakims and registered AYUSH practitioners only, who have been practising indigenous medicines, including Indian systems of medicine as profession for sustenance and livelihood are exempted under Section 7 of the Act.
  4. Conventional breeding: Accessing biological resources for conventional breeding or traditional practices in use in any agriculture, horticulture, poultry, dairy farming, animal husbandry or beekeeping, in India {Section 2(f)}.
  5. Academic dissemination: Publication of research papers or dissemination of knowledge, in any seminar or workshop involving financial benefit, if such publication is in conformity with the guidelines issued by the Central Government from time to time (first proviso clause to Section 4).
  6. Collaborative research: Transfer or exchange of biological resources or TK under collaborative research projects between Government-sponsored institutions and such institutions in other countries are exempted subject to conformity to the policy guidelines issued by the Central Government (Section 5).
  7. Normally traded as commodities: Biological resources when normally traded as commodities or to the items derived from them, including agricultural wastes, as notified and cultivated medicinal plants and their products for entities covered under Section 7, registered as per the regulations made or as may be prescribed, notified by the Central Government (Section 40).
  8. Crops under ITPGRFA: Accessing the crops from amongst the crops listed at Annex-I of the International Treaty on Plant Genetic Resources for Food and Agriculture (ITPGRFA), as notified by the Department of Agriculture and Cooperation, Ministry of Agriculture, Government of India from time to time, is exempted from the provisions of Sections 3 and 4 of the Act, for the purpose of utilization and conservation for research, breeding and training for food and agriculture.
  9. Approvals under the PPVFRA: Any person who has been given any approval or granted any right under any law relating to protection of plant varieties enacted by the Parliament to the extent that such approvals or rights given under that Act does not require similar approval under the BD Act (Section 59-A).

37. What is the benefit-sharing component payable to the NBA by the applicant for accessing the biological resources for commercial utilisation?

As per regulation 4 of the BD (ABS) Regulations, 2025, the applicant shall have to pay the benefit sharing amount to the NBA as per the slabs prescribed below:

Sl. No.Annual turnover of the entity (in Indian rupee)Amount payable on account of benefit sharing for access to biological resource for commercial utilisation (Percentage of annual gross ex-factory sale price of product excluding Government taxes)
(1)(2)(3)
1.Up to 5 croreNil
2.Above 5 crore to 50 crore0.2%
3.Above 50 crore to 250 crore0.4%
4.Above 250 crore0.6%

Biological resources having conservation or high economic value, including species notified under Section 38 of the Act are subject to 20% more than the benefit sharing due.

If access is made to a biological resource that has conservation value, or high economic value such as red sanders, sandalwood, agarwood, or any other item identified by the Authority, including threatened species listed under Section 38 of the Act, the ABS component shall not be less than five percent of the proceeds of the auction or sale amount, or purchase price, as the case may be. This amount will be decided by the Authority on a case-by-case basis and must be paid as an upfront payment.

38. What are the forms applicable for IPR?

e-FormsPurpose of the application
6Application for seeking prior approval to use the results of research for obtaining IPR by the transferee (Section 3(2) entity).
7Application for seeking prior approval of the NBA before grant of IPR by persons covered under Section 3 (2) of the Act.
8Application for registration with the NBA before grant of IPR by persons covered under Section 7 of the Act.
9Application for seeking prior approval of the NBA for commercialisation of IPR by persons covered under Section 7 of the Act.
Applications are available in ABS e-filing portal

39. Are there specific Rules governing the implementation of the Biological Diversity Act? Have any amendments been made to these Rules?

Yes. - The Biological Diversity Rules, 2004 were notified by the Ministry of Environment, Forest and Climate Change (MoEFCC) on April 15, 2004 which came into force on July 01, 2004.

Pursuant to the amendments to the BD Act in 2023, the MoEFCC notified the Biological Diversity Rules, 2024 on October 22, 2024, thereby superseding the BD Rules, 2004. The BD Rules, 2024 came into force on December 21, 2024 upon expiry of 60 days from the date of notification in accordance with rule 1(2) of the BD Rules, 2024.

Further the BD Rules, 2024 were amended vide Biological Diversity (Amendment) Rules, 2025 which were notified on May 06, 2025 and came into force on November 01, 2025.

40. What constitutes an approval under this Act? How will I be informed about the approval of my application by the NBA to access a biological resource?

Approval shall be granted in the form of an agreement executed between the applicants and the NBA. The agreement shall contain the benefit sharing component, terms and conditions subject to which the applicant shall access the biological resources for research/commercial utilization/bio-survey and bio-utilization/IPR.

FAQ Disclaimer

Version of FAQ: 

Date of FAQ: